The labor market has been forever changed by COVID-19. However, the changes in recruiting and retaining talent in pharma marketing and advertising started well before the pandemic. The traditional, linear career development path is not necessarily standard anymore, and the industry is looking in a variety of areas for talented professionals. MedAdNews asked several of its editorial advisory board members to reflect and weigh in on how the talent pool has changed over the years.
If you are not happy with the results below please do another search
50 search results for:
Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.
For our 40th Anniversary Edition, we asked our editorial advisory board members to talk about the most significant strides they’ve seen over the course of their careers, how client challenges have changed, thoughts on talent and recruitment strategies, and trends that are advancing the industry. Obviously one of the biggest changes has been the role of digital technology and its part in personalization. But frankly, we barely scratched the surface!
There has been an emphasis on the use of real-world data and real-world evidence in crafting messages for payers. But experts say the insights generated by RWD and RWE are extremely useful in understanding clinicians and patients.
The greatest power of the new marketing technologies available to pharma brands may be their capacity to bring the beliefs and questions of real patients and HCPs into sharper view.
The top performers among drugs launched in 2020 were each the first of their kind.
The biopharma industry’s response to the global pandemic has propelled some COVID-19 vaccines into the leading ranks of the world’s best-selling products, with Pfizer/BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot.
The naming of brands is a difficult matter.
Being expedient focuses on today’s challenges and needs, and often means skipping steps, estimating rather than calculating, and doing things quickly. Sometimes the expedient solution is necessary; however, it inevitably leads to more work down the road. This is the essence of efficiency – not just fast, but without wasted time and effort.
While preventive care is vital to the well-being of all types of patients, members of the lesbian, gay, bisexual, transgender and queer and/or questioning community face unique barriers that impact their preventive health awareness and access – setting many of them up for poorer overall health outcomes and even impacting their trust in pharma.